CJC-1295
Also known as: CJC-1295 DAC, Drug Affinity Complex-GHRH, Modified GHRH 1-29
Overview
CJC-1295 is a 29-amino acid synthetic analog of growth hormone-releasing hormone (GHRH), structurally based on the first 29 amino acids of native GHRH with four amino acid substitutions to improve stability, plus an attached Drug Affinity Complex (DAC) component. The DAC modification allows covalent binding to serum albumin, dramatically extending the half-life to several days and enabling sustained GH and IGF-1 elevation lasting up to 28 days after a single dose.
Mechanism of Action
CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, activating G-proteins and downstream second messengers (cAMP, IP₃). This triggers protein kinase cascade activation and transcription factor phosphorylation, ultimately driving GH gene transcription and GH secretion. Studies indicate 2-10 fold increases in GH pulse amplitude and 1.5-3 fold increases in IGF-1 levels, with the DAC modification providing sustained albumin-bound reservoir activity.
Potential Benefits
- 2-10 fold increase in growth hormone pulse amplitude
- 1.5-3 fold increase in IGF-1 levels sustained for up to 28 days
- Potential increase in lean muscle mass (~2.77 lbs over 16 weeks in early studies)
- Improved fat metabolism and body composition
- Enhanced recovery and repair processes
- Anti-aging effects via GH/IGF-1 axis optimization
- Prolonged half-life allowing less frequent dosing compared to native GHRH
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 100-300 mcg/dose, 1-3x/week |
| Beginner | 100 mcg 2x/week |
| Intermediate | 200 mcg 2-3x/week |
| Advanced | 300 mcg 3x/week |
| Cycle Duration | 8-12 weeks |
| Cycle Off | 4-8 weeks |
CJC-1295 with DAC is typically dosed 1-2x/week due to extended half-life. Without DAC (Modified GRF 1-29), dose daily or before sleep. Combine with a GHRP for synergistic GH release (GHRH+GHRP is the gold standard stack).
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High — extended release (DAC version: 6–8 day half-life; non-DAC: ~30 min)
Standard method. DAC version: 1–2 mg weekly. Non-DAC (mod-GRF 1-29): 100 mcg 1–3x daily, paired with a GHRP.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving CJC-1295:
Standard GH Stack
Synergistic GH release — CJC-1295 amplifies GHRH signaling while Ipamorelin provides clean, selective GH pulses. Most widely used GH peptide combination.
Recovery & Growth Stack
Full recovery protocol. GH elevation from CJC-1295/Ipamorelin enhances the tissue-healing effects of BPC-157 and TB-500.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 2mg, 5mg |
|---|---|
| BAC Water | 1-2ml per 2mg vial |
| Storage | Refrigerate at 2-8°C after reconstitution |
| Shelf Life | 28 days refrigerated; stable lyophilized for 24+ months at -20°C |
Need exact syringe measurements?
Amino Acid Sequence
Tyr-DAla-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Mpa)-NH2 (DAC conjugated)
Side Effects & Safety
- Water retention and bloating
- Increased hunger/appetite stimulation
- Tingling or numbness in extremities
- Potential insulin resistance with long-term use
- Joint pain at high doses
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Active Malignancy
Uncontrolled Diabetes Mellitus
Severe Cardiac Disease
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Drug Interactions
- Insulin / Oral Hypoglycemics:
FDA Safety Information
FDA Category 2 concerns: immunogenicity, serious adverse events (increased heart rate, vasodilatory reaction).
Pharmacokinetics
| Half-Life | DAC version: 6-8 days; No-DAC (Modified GRF 1-29): ~30 minutes |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside CJC-1295 for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.